| Project/Area Number |
18K07865
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52050:Embryonic medicine and pediatrics-related
|
|---|
| Research Institution | National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders |
|---|
Principal Investigator |
Takahashi Yukitoshi 独立行政法人国立病院機構(静岡・てんかん神経医療センター臨床研究部), その他部局等, その他 (70262764)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | AMPA型GluR / 自己抗体 / 行動異常 / てんかん / 学習障害 / 脳炎 / 胸腺腫 / 非ヘルペス性急性辺縁系脳炎 / 免疫介在性脳炎 / AMPA型GluR抗体 / 痙攣 |
|---|
| Outline of Final Research Achievements |
We constructed HEK293T cells expressing GluA1, GluA2, GluA3,or GluA4 with EGFP-conjugated vectors, and established immune screening system for antibodies to GluA1, GluA2, GluA3,or GluA4.In the preliminary screening for antibodies to AMPA-type GluRs using CSF from 38 patients of neurological diseases, we found antibodies to GluA1 in two patients, antibodies to GluA2 in one patients, antibodies to GluA3 in one patients, and antibodies to GluA4 in one patients.
|
| Academic Significance and Societal Importance of the Research Achievements |
ヒトAMPA型GluR（GluA1、GluA2、GluA3、GluA4の各サブユニット）とEGFPの融合タンパクを発現できるベクターを導入したHEK293T細胞を作成し、AMPA型GluR抗体検出が可能となった。今後、AMPA型GluR抗体による神経免疫疾患の診断が可能となり、早期免疫治療が可能となり、予後が改善できる。
|
